News
IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer’s Disease
India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”), announced that it has begun “A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Trial of the
onsemi Divests Niigata, Japan Fab
onsemi (Nasdaq: ON), a leader in intelligent power and sensing technologies, today announced the completion of the sale of its Niigata, Japan facility to JS Foundry K.K. The divestiture aligns with
VICI Properties Inc. to Acquire Remaining 49.9% Interest in MGM Grand Las Vegas and Mandalay Bay Joint Venture From Blackstone Real Estate Income Trust, Inc.
Blackstone Real Estate Income Trust, Inc. (“BREIT”) and VICI Properties Inc. (NYSE: VICI) (“VICI Properties” or “VICI”) announced jointly today that they have entered into a definitive agreement in
Christian Mäder to take over as CFO of the Komax Group on 1 October 2023
EQS-Adhoc: paragon sells AI subsidiary paragon semvox to CARIAD
EQS-News: ADVA Optical Networking SE: Extraordinary general meeting approves domination and profit and loss transfer agreement and elects supervisory board members
UiPath Announces Global Partnership with Orica to Scale Application Testing and Automation Capabilities, Deliver Enterprise-wide Process Efficiencies
UiPath (NYSE:PATH), a leading enterprise automation software company, and Orica (ASX: ORI), one of the world’s largest mining and infrastructure solutions providers, today announced a global
Charles River Launches Endosafe Nexus 200, Emphasizes Critical Importance of Smart Automation for Endotoxin Detection
Charles River Laboratories International, Inc. (NYSE: CRL) launches the Endosafe® Nexus 200™, expanding its robust endotoxin testing portfolio. The Nexus 200 is the next evolution of Charles
NICE Actimize Positioned as Overall Leader in the 2022 Quadrant Knowledge Trade Surveillance and Monitoring Report
NICE Actimize, a NICE (Nasdaq: NICE) business, has been ranked by global advisory and consulting firm Quadrant Knowledge Solutions as the overall global Leader in its report titled “SPARK Matrix™
Form 8.3 - Maitland Institutional Services Limited: Re Devro plc
REX American Resources Reports Third Quarter Net Income Per Share Attributable to REX Common Shareholders Of $0.18
REX American Resources Corporation (NYSE: REX) (“REX” or “the Company”) today reported financial results for its fiscal 2022 third quarter (“Q3 ‘22”) ended October 31, 2022. REX management will
BitNile Holdings Issues November Bitcoin Production and Mining Operation Report
BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“BitNile” or the “Company”) today published an unaudited update on Bitcoin production and miner installation. The number
Rights and Issues Investment Trust PLC: Net Asset Value(s)
EQS-News: Allterco JSCo updates invitation and documents to Extraordinary General Meeting of Shareholders
Chelverton UK Dividend Trust plc: Net Asset Value(s)
U.K. Banks Modernize to Meet Regulatory, Market Demands
Banks in the U.K. are carrying out large-scale technology transformations in response to evolving regulations, changing customer expectations and the emergence of new innovations and competitors
Nass Valley Gardens Announces It Has Contracted Its Reg A+ Capital Raise Team
Rights and Issues Investment Trust PLC: Total Voting Rights
CORRECTION: JSC Halyk Bank - On the completion of the transaction on the sale of 100% shares of a subsidiary in Tajikistan
Nordic Banks Accelerate Changes Amid Market Shake-up
Banks in the Nordics are going through significant technology and business transitions, moving from legacy systems to new cloud-based platforms and products in response to new competition and
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases
AbCellera (Nasdaq: ABCL) and Rallybio Corporation (Nasdaq: RLYB) announced today that they have entered into a strategic alliance to discover, develop, and commercialize novel antibody-based